Neuroendocrine Tumor Treatment Depends on Site, Grade, and Spread

You have been told you have a neuroendocrine tumor, and the first thing you want to know is simple: what happens now?

The honest answer is that there is no single answer. Treatment for a neuroendocrine tumor is built around your situation: where the tumor started, how quickly it is growing, whether it makes hormones, and whether it has spread.

That is not bad news. Many of these tumors can be kept under control for years with a planned combination of monitoring, surgery, medicines, and specialist treatments.

Overview: how neuroendocrine tumor treatment works

The goals are straightforward: remove the tumor if that can be done, slow or stop its growth if it has spread, settle any hormone-related symptoms, and protect how you feel day to day. The best plan depends on the tumor’s site of origin, grade (how abnormal the cells look under a microscope), stage, growth rate, hormone production, and the presence of treatment targets such as somatostatin receptors.

Neuroendocrine tumors, often called NETs, can develop in several organs. Many start in the small bowel, pancreas, rectum, appendix, lungs, or stomach. Some are functional, meaning they release hormones that cause symptoms such as flushing, diarrhea, wheezing, low blood sugar, or recurrent ulcers. Others are nonfunctional and may be found after imaging or investigations for nonspecific symptoms.

Care is usually coordinated by a multidisciplinary team that may include medical oncologists, endocrine specialists, surgeons, gastroenterologists, radiologists, nuclear medicine physicians, pathologists, dietitians, and supportive-care clinicians. Treatment decisions are commonly reviewed at a tumor board, particularly for complex or metastatic disease.

How treatment choices are made and who may be a candidate

Before recommending neuroendocrine tumor treatment, clinicians confirm the diagnosis and establish the tumor’s behavior. A biopsy can identify the type of NET and its grade, often using the Ki-67 index and cell appearance. CT or MRI scans show the location and extent of disease, while specialized receptor imaging may show whether the tumor takes up somatostatin-based tracers.

A person may be considered for surgery if the tumor is localized or if removing it can safely reduce symptoms or tumor burden. Somatostatin analogue medicines may be appropriate for well-differentiated NETs that express somatostatin receptors, especially when hormone symptoms or tumor growth need control. Other options are selected according to the primary site, grade, liver involvement, previous treatment, and individual goals.

Not every NET needs treatment straight away. For a small, low-grade tumor that is not causing symptoms and appears stable on scans, a specialist may recommend active surveillance with scheduled imaging and clinical review. That is a plan, not neglect — and it can be changed the moment the tumor does.

Treatment options and what happens during treatment

Surgery is often the main treatment for localized NETs. The procedure varies by tumor location and can involve removal of the tumor, part of an affected organ, nearby lymph nodes, or selected areas of liver disease. The surgical team considers whether the tumor can be removed safely and whether surgery is likely to improve long-term control or symptoms.

Somatostatin analogues are long-acting medicines given by injection that can reduce hormone-related symptoms and may slow growth in some well-differentiated NETs. Other systemic treatments may include targeted medicines, chemotherapy, or immunotherapy in selected situations. Chemotherapy is more commonly considered for certain pancreatic NETs or poorly differentiated, high-grade neuroendocrine cancers, which can behave more aggressively.

Peptide receptor radionuclide therapy (PRRT) combines a somatostatin-like molecule with a radioactive substance. It is delivered through a vein and travels to tumors with suitable somatostatin receptors, delivering radiation mainly to those cells. Peptide receptor radionuclide therapy (PRRT) may be considered for eligible, receptor-positive NETs that have progressed despite other treatment.

When disease is concentrated in the liver, liver-directed approaches such as embolization, radioembolization, ablation, or carefully selected surgery may help reduce tumor burden or hormone symptoms. The exact sequence of treatments differs widely, so a plan should be individualized rather than based on one standard pathway.

A practical treatment journey: preparation, recovery and follow-up

The treatment journey usually starts with pathology review, staging scans, blood tests, and a discussion of symptoms, current medicines, nutrition, and personal priorities. Some people need additional procedures before treatment, such as endoscopy, receptor imaging, or assessment of heart function when longstanding hormone excess is suspected. The care team explains the purpose of each test and how results guide the next step.

For surgery, preparation may include anesthesia assessment, medication adjustments, and nutritional planning. Recovery depends on the operation performed. A minimally invasive procedure may involve a shorter hospital stay and recovery period than major abdominal surgery, but all patients need individualized advice about wound care, activity, diet, pain control, and warning symptoms after discharge.

For injection therapies, tablets, intravenous treatments, or PRRT, visits are usually scheduled at defined intervals with blood tests and imaging before or between cycles. Temporary fatigue, nausea, bowel changes, or changes in appetite can occur with some treatments. PRRT also requires monitoring of blood counts and kidney function, and the nuclear medicine team provides radiation-safety instructions for the period after treatment.

Follow-up is long term. Clinicians monitor scans, relevant laboratory markers, treatment effects, hormone symptoms, weight, and quality of life. Stable imaging does not necessarily mean follow-up stops; instead, the interval between visits may be adjusted according to the tumor type and clinical situation.

Benefits, limitations and possible risks

Potential benefits of neuroendocrine tumor treatment include complete removal of localized disease, slower tumor growth, symptom relief, prevention of complications, and improved comfort and function. For advanced NETs, treatment may focus on long-term disease control rather than cure. A clear conversation about the aim of each option helps people make informed decisions.

Every treatment has possible risks. Surgery can involve bleeding, infection, blood clots, injury to nearby structures, and changes in digestion or hormone balance depending on the organ treated. Medication side effects differ by drug but can include digestive symptoms, fatigue, changes in blood sugar, skin effects, or altered blood counts. Liver-directed and radionuclide treatments also have specific risks that require specialist monitoring.

Supportive care is appropriate at every stage and may include symptom management, dietary advice, emotional support, and help with treatment-related fatigue or pain. It is not just for the end of life. People should tell their team about new symptoms, complementary products, or concerns about work, family responsibilities, fertility, or travel so that support can be tailored.

How long do people live with neuroendocrine tumors?

How long someone lives with a neuroendocrine tumor varies enormously, and the diagnosis on its own tells you very little. Important factors include the tumor’s primary site, grade, stage, pace of growth, response to treatment, overall health, and whether it can be completely removed. Many well-differentiated NETs grow slowly, and some people live for many years with regular monitoring and treatment when needed.

Higher-grade or poorly differentiated neuroendocrine cancers can grow and spread more quickly, so their outlook and treatment approach are different. The treating specialist can provide the most meaningful individual discussion after reviewing pathology, imaging, and response over time. Treat survival figures with care: they describe large groups of people, not you.

Can neuroendocrine cancer go into remission?

Yes, neuroendocrine cancer can go into remission in some circumstances, particularly when a localized tumor is fully removed with surgery and follow-up tests show no evidence of disease. Remission means there are no detectable signs of cancer at that time; it does not always mean the cancer can never return. Ongoing surveillance remains important because recurrence can occur years later in some tumor types.

For metastatic NETs, complete remission is less common, but treatment can often shrink tumors, keep them stable, and control symptoms for meaningful periods. Imaging results, symptoms, and laboratory tests are assessed together to determine whether disease is responding, stable, or progressing.

What is the most effective treatment for neuroendocrine cancer?

No one treatment works best for every neuroendocrine cancer. Surgery is generally the preferred potentially curative treatment when the tumor is localized and can be removed safely. However, the most appropriate option for an individual may instead be observation, hormone-controlling medication, PRRT, targeted therapy, chemotherapy, liver-directed treatment, or a combination of approaches.

The tumor’s grade and receptor status are especially important. Well-differentiated, receptor-positive NETs may respond well to somatostatin-based medicines or PRRT, while high-grade neuroendocrine carcinomas may require chemotherapy more urgently. A specialist team can explain which treatments are supported by the tumor’s specific features.

How fast does a neuroendocrine tumor grow?

Neuroendocrine tumors can grow at very different rates. Many well-differentiated NETs are slow growing and may remain stable for long periods, whereas high-grade neuroendocrine carcinomas can grow rapidly. Grade, Ki-67 index, imaging changes over time, symptoms, and the rate of spread help clinicians estimate behavior.

You cannot judge growth from how you feel. Scheduled scans allow the care team to compare tumor size and distribution over time. If a person develops new or worsening symptoms between planned appointments, they should contact their healthcare team rather than waiting for the next scan.

When to seek medical care

Medical assessment is advisable for persistent or unexplained flushing, frequent watery diarrhea, wheezing episodes, recurrent abdominal pain, unexplained weight loss, jaundice, blood in the stool, or symptoms of low blood sugar. These symptoms are common and often have causes other than a NET, but they deserve evaluation when they are ongoing, severe, or changing.

People already diagnosed with a NET should contact their clinical team promptly for rapidly worsening pain, persistent vomiting, dehydration, new yellowing of the skin or eyes, severe shortness of breath, fainting, or a sudden marked change in flushing or diarrhea. Emergency care is appropriate for severe symptoms or signs of an acute medical problem.

Acıbadem Health Point’s multidisciplinary specialists and JCI-accredited hospitals assess and treat neuroendocrine tumors for international patients, with care coordinated across oncology, surgery, imaging, nuclear medicine, and supportive services. A second opinion may also be helpful when diagnosis, tumor grade, or treatment sequencing is uncertain.

Frequently asked questions